ProMIS Neurosciences just converted a long-running oligomer thesis into a concrete safety observation that the approved amyloid antibodies have not delivered. In late July the company reported a blinded six-month look at PRECISE-AD, its mid-stage study of PMN310 in early Alzheimer disease, and recorded zero cases of ARIA-E, the edema that has limited lecanemab and donanemab in high-risk genotypes. That is the event. The antibody is designed to bind toxic soluble oligomers and leave plaque alone, and a clean edema print is the first human test of whether that design choice is more than a slide.
The counterargument is that the dataset is still blinded and the biomarker moves are pooled. Plasma p-tau217 declined about fifteen percent and a cerebrospinal fragment of tau moved in the same direction, with responder rates that roughly match the three-to-one active allocation. That is consistent with target engagement, not proof of it. The study enrolled 144 patients. The interim covered 136 of them. Cash rebuilt to $53 million after a January private placement, which management presents as runway through next year and past the unblinded twelve-month readout. Almost as many warrants sit over the stock as common shares, and the large January strip can be called shortly after that topline.
The print that matters is not another interim. It is whether the unblinded twelve-month package, expected in the first quarter of next year, keeps the edema rate near zero and shows a cognitive signal large enough to support a single registration study. If the safety holds and cognition is only directional, the equity remains a partnership option. If both legs land, the warrant strip becomes a capital event rather than an overhang. Does the current price pay for a safety option, or for a registrational Alzheimer antibody that has not yet been unblinded?